EUVIMEDEUVIMED entdecken
Crossref

Eating Disorder Risk and Screening in Patients Using GLP ‐ 1RAs : Lessons Learned From Metabolic and Bariatric Surgery

Kirstie M Herb Neff iD, Ashley Dunford iD, Andrea B Goldschmidt iD, Kelly C Allison iD, Alexis Richeson iD

International Journal of Eating Disorders · 2026-11 · 59 (11) · 2370-2374

DOI: 10.1002/eat.70180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Eating Disorders, online erschienen am 26.07.2026. Verfasst von Kirstie M Herb Neff und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Health Sciences, Geisinger College of Health Sciences, Danville, Pennsylvania, USA. Hauptthemen laut MEDLINE: Bariatric Surgery, Feeding and Eating Disorders, Glucagon-Like Peptide-1 Receptor Agonists, Obesity. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are increasingly prescribed for weight management. Similar to the early implementation of metabolic and bariatric surgery (MBS), little is known about how GLP‐1RAs affect individuals with eating disorders (EDs) or their potential to promote, mask, or exacerbate ED psychopathology. Lacking robust empirical data directly examining associations between GLP‐1RAs and ED risk, we draw on lessons from the field of MBS to summarize current critical knowledge gaps and guide clinicians, educators, researchers, and advocates on interim decision‐making.

Method

As providers working at the intersection of EDs and obesity treatment, we integrate published findings with our clinical and research expertise to identify potential ED risks associated with GLP‐1RA use and identify opportunities to screen and intervene.

Results

Initially in MBS practice, ED symptoms were underrecognized due to lack of standardized screening and monitoring protocols. Early concerns arose from patient reports and provider observations, followed by empirical and systematic research investigation leading to the development of structured assessment tools and protocols. Similar concerns are arising with GLP‐1RA treatment, where changes in appetite and weight may, without prospective or ongoing screening, worsen existing or contribute to de novo ED behaviors and cognitions.

Conclusion

ED providers are uniquely positioned to identify and address disordered eating occurring with GLP‐1RA treatment that may be overlooked by providers with less ED training and experience. We highlight opportunities for ED professionals to engage in advocacy, education, and interdisciplinary collaboration to reduce harm and promote patient wellbeing as GLP‐1RA use increases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bariatric SurgeryFeeding and Eating DisordersGlucagon-Like Peptide-1 Receptor AgonistsObesityHumans

Stichwörter der Autor:innen

GLP‐1RAsbinge eatingeating disorder riskfeeding and eating disordersglucagon‐like peptide‐1 receptor agonistshigher weightmetabolic and bariatric surgeryobesityrestrictive eatingscreening

Substanzen

Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Population Health Sciences, Geisinger College of Health Sciences, Danville, Pennsylvania, USA.
  • Center for Obesity and Metabolic Research, Geisinger College of Health Sciences, Danville, Pennsylvania, USA.
  • Eating Disorders Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Psychiatry, University of Pittsburg School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Kirstie M Herb Neff, Ashley Dunford, Andrea B Goldschmidt, Kelly C Allison, Alexis Richeson

Förderung

  • Novo Nordisk

Zitieren

APA

Herb Neff, K. M., Dunford, A., Goldschmidt, A. B., Allison, K. C., & Richeson, A. (2026). Eating Disorder Risk and Screening in Patients Using GLP ‐ 1RAs : Lessons Learned From Metabolic and Bariatric Surgery. International Journal of Eating Disorders, 59(11), 2370-2374. https://doi.org/10.1002/eat.70180

Vancouver

Herb Neff KM, Dunford A, Goldschmidt AB, Allison KC, Richeson A. Eating Disorder Risk and Screening in Patients Using GLP ‐ 1RAs : Lessons Learned From Metabolic and Bariatric Surgery. International Journal of Eating Disorders. 2026;59(11):2370-2374. doi:10.1002/eat.70180

BibTeX
@article{HerbNeff2026,
  author = {Herb Neff, Kirstie M and Dunford, Ashley and Goldschmidt, Andrea B and Allison, Kelly C and Richeson, Alexis},
  title = {Eating Disorder Risk and Screening in Patients Using GLP ‐ 1RAs : Lessons Learned From Metabolic and Bariatric Surgery},
  journal = {International Journal of Eating Disorders},
  year = {2026},
  volume = {59},
  number = {11},
  pages = {2370--2374},
  doi = {10.1002/eat.70180}
}
Kostenlos starten →